Point mutations within the Abl kinase domain that interfere with imatinib binding are the most critical cause of imatinib resistance. In order to override this resistance, several second ...
most patients with advanced disease develop drug resistance associated with mutations in the ABL kinase domain. Reporting in Nature, Gray and colleagues identify and characterize a selective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback